Peripheral transcriptome of clinical high‐risk psychosis reflects symptom alteration and helps prognosis prediction.

Clinical high-risk psychosis (CHR-P)1 refers to a heterogeneous state where patients exhibit psychotic syndromes such as hallucination and delusion not reaching the diagnostic criteria, with the ability of self-reasoning and help-seeking partially maintained. Thus, blood transcriptome is valuable to CHR-P's clinical intervention, where treatment choices are dependent on the objective evaluation of symptom severity and conversion risk.9 In addition, our symptom association model also reflected the underlying biological mechanism, such as downregulation of synaptic vesicle recycling during CHR-P progression. Methods To evaluate whether blood RNA could serve as CHR-P biomarkers, we collected blood samples of patients with CHR-P from the Shanghai at-risk psychosis (SHARP) longitudinal cohort7 and applied RNA sequencing. Peripheral transcriptome of clinical high-risk psychosis reflects symptom alteration and helps prognosis prediction. [Extracted from the article]